Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
about
Targeting the Checkpoint to Kill Cancer CellsNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingTargeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.Dynamic In Vivo Profiling of DNA Damage and Repair after Radiotherapy Using Canine Patients as a Model.A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR InhibitorsEfficacy of ATR inhibitors as single agents in Ewing sarcoma.Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy.HBXIP, a binding protein of HBx, regulates maintenance of the G2/M phase checkpoint induced by DNA damage and enhances sensitivity to doxorubicin-induced cytotoxicity.The DNA damage response pathway in normal hematopoiesis and malignancies.Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis.Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib.
P2860
Q26795781-FF7BA335-5720-43D3-9F6C-F25295465B0EQ27304386-27683DEF-7094-4069-8FBD-224765CE5002Q28468631-719DDEAB-2187-4886-A95C-DC3447F43DC8Q30823304-9E7EE209-BB2F-438B-AE8A-E1798A3270B7Q33838607-EAB2B6FA-40E7-45F1-BF3B-4189305CA7D9Q37268724-DF2BBCA1-B252-4969-8413-8471A1FDADD5Q37644764-A8FF2AC4-0801-48D0-9C95-7FC332EEE1ECQ38504989-B917A31E-D193-4EEB-B212-9DD21F249DDBQ38756843-7B44D912-FD99-468E-8E31-509779CF822CQ39001598-B87DFE0D-8256-44A3-B48C-52F4085988A9Q39012457-9FA49FA3-A6ED-410D-AFA0-FA04FED3F0E4Q39434457-75769828-7112-4E45-A9BB-556BED878C33Q42861612-B84E50F5-AC57-46ED-8C27-64CD5613819FQ47120183-16CAC975-E204-4C36-B612-EC27D6A79636Q48250645-720EF3D4-4103-4516-BE7E-5FF05F6A6EE7Q50128397-CE7C357A-038A-4908-A081-FFE37CDE8FBEQ52681376-3701449D-8A2A-4312-9277-2B54CA261128Q55221402-79FB9E21-AF48-4EB1-B820-4D6A38422650
P2860
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Constitutive activation of the ...... diffuse large B-cell lymphoma
@ast
Constitutive activation of the ...... diffuse large B-cell lymphoma
@en
type
label
Constitutive activation of the ...... diffuse large B-cell lymphoma
@ast
Constitutive activation of the ...... diffuse large B-cell lymphoma
@en
prefLabel
Constitutive activation of the ...... diffuse large B-cell lymphoma
@ast
Constitutive activation of the ...... diffuse large B-cell lymphoma
@en
P2093
P2860
P50
P356
P1433
P1476
Constitutive activation of the ...... diffuse large B-cell lymphoma
@en
P2093
Elisa Brighenti
Enrica Imbrogno
Enrico Derenzini
Fabio Fuligni
Giovanni Martinelli
Ilaria Iacobucci
Simona Righi
Stefano Pileri
P2860
P304
P356
10.18632/ONCOTARGET.2720
P407
P577
2015-03-01T00:00:00Z